Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive …
N Horita, A Goto, Y Shibata, E Ota… - Cochrane Database …, 2017 - cochranelibrary.com
N Horita, A Goto, Y Shibata, E Ota, K Nakashima, K Nagai, T Kaneko
Cochrane Database of Systematic Reviews, 2017•cochranelibrary.comBackground Three classes of inhaler medications are used to manage chronic obstructive
pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic
antagonists (LAMA), and inhaled corticosteroids (ICS). When two classes of medications are
required, LAMA plus LABA (LAMA+ LABA) and LABA plus ICS (LABA+ ICS) are often
selected because these combinations can be administered via a single medication device.
The previous Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidance …
pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic
antagonists (LAMA), and inhaled corticosteroids (ICS). When two classes of medications are
required, LAMA plus LABA (LAMA+ LABA) and LABA plus ICS (LABA+ ICS) are often
selected because these combinations can be administered via a single medication device.
The previous Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidance …
Background
Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long‐acting beta‐agonists (LABA), long‐acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS). When two classes of medications are required, LAMA plus LABA (LAMA+ LABA) and LABA plus ICS (LABA+ ICS) are often selected because these combinations can be administered via a single medication device. The previous Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidance recommended LABA+ ICS as the first‐line treatment for managing stable COPD in high‐risk people of categories C and D. However, the updated GOLD 2017 guidance recommends LAMA+ LABA over LABA+ ICS.
Objectives
To compare the benefits and harms of LAMA+ LABA versus LABA+ ICS for treatment of people with stable COPD.
cochranelibrary.com
